World Congress

Gordian Biotechnology Introduces High-Throughput In Vivo Screening Platform to Discover Therapies and Better Predict Human Outcomes for Age-Related Diseases

Retrieved on: 
Friday, April 26, 2024
Founders Fund, FDA, OA, Patient, Horse, Cell, Notifiable disease, Animal, OARSI, Osteoarthritis Research Society International, Infection, Entrepreneurship, Research, Pathology, Artificial intelligence, Disease, Human, Novartis, Therapy, Ageing, Pulmonary fibrosis, Osteoarthritis, Gene, Biology, Drug discovery, Longevity, World Congress, MASH, Heart failure, Pharmaceutical industry

SAN FRANCISCO, April 26, 2024 /PRNewswire/ -- Gordian Biotechnology, an in vivo drug discovery and development company, today announced its platform that enables patient predictive, in vivo screening of hundreds of gene targets for FDA-recognized diseases of aging at a scale never before possible.

Key Points: 
  • Gordian's Osteoarthritis (OA) program has screened hundreds of therapies in horses that acquired OA naturally and advanced dozens of therapies into human ex vivo validation studies.
  • In proof of concept experiments during initial development, Gordian introduced a pooled library of 50 gene therapies into a mouse model of metabolic-associated steatohepatitis (MASH).
  • The therapies were evaluated using the company's proprietary in vivo screening platform, which successfully recapitulated 13 out of 16 clinical outcomes for targets where clinical data exists.
  • Mosaic Screening™ is pooled in vivo screening that tests hundreds of therapies simultaneously in a single sick animal, the Patient Avatar.

Peter Eckes, Former CTO of BASF Agricultural Solutions, to Chair Harpe Bioherbicide Board

Retrieved on: 
Wednesday, April 17, 2024
Congress, Peter, University, UN, Seed, University of Western Australia, Eckes, BASF, Organic, North Carolina State University, Life, Farmer, Desiccation, Crop protection, Weed control, Associate, World Congress, Harpe, Management

RESEARCH TRIANGLE PARK, N.C., April 17, 2024 /PRNewswire/ -- Harpe Bioherbicide Solutions, Inc., an agricultural technology company focused on providing natural and sustainable herbicide solutions, announced today that Dr. Peter Eckes, former President of BASF leading Crop Protection R&D, Seed and Trait R&D and Regulatory in the Agricultural Solutions division, has joined its board and will serve as board chairperson.

Key Points: 
  • "Harpe has both a compelling value proposition and strong business plan to bring new and natural weed control innovations to life," said Eckes.
  • Eckes assumes board leadership from Aidan J. Connolly, President of AgriTech Capital, who will remain as a Harpe Bioherbicide board member.
  • Additional Harpe Bioherbicide board members include CEO Buckner; Kip Tom, CEO of Tom Farms and former UN Ambassador; Robb Fraley, former CTO for Monsanto Co.; Chad Brommer, Harpe Bioherbicide co-founder and CTO; and Daniel Pepitone, Harpe Bioherbicide co-founder and COO.
  • Those attending are invited to visit Booth #22 to learn more about Harpe Bioherbicide formulations.

Peter Eckes, Former CTO of BASF Agricultural Solutions, to Chair Harpe Bioherbicide Board

Retrieved on: 
Wednesday, April 17, 2024
Congress, Peter, University, UN, Seed, University of Western Australia, Eckes, BASF, Organic, North Carolina State University, Life, Farmer, Desiccation, Crop protection, Weed control, Associate, World Congress, Harpe, Management

RESEARCH TRIANGLE PARK, N.C., April 17, 2024 /PRNewswire/ -- Harpe Bioherbicide Solutions, Inc., an agricultural technology company focused on providing natural and sustainable herbicide solutions, announced today that Dr. Peter Eckes, former President of BASF leading Crop Protection R&D, Seed and Trait R&D and Regulatory in the Agricultural Solutions division, has joined its board and will serve as board chairperson.

Key Points: 
  • "Harpe has both a compelling value proposition and strong business plan to bring new and natural weed control innovations to life," said Eckes.
  • Eckes assumes board leadership from Aidan J. Connolly, President of AgriTech Capital, who will remain as a Harpe Bioherbicide board member.
  • Additional Harpe Bioherbicide board members include CEO Buckner; Kip Tom, CEO of Tom Farms and former UN Ambassador; Robb Fraley, former CTO for Monsanto Co.; Chad Brommer, Harpe Bioherbicide co-founder and CTO; and Daniel Pepitone, Harpe Bioherbicide co-founder and COO.
  • Those attending are invited to visit Booth #22 to learn more about Harpe Bioherbicide formulations.

Eupraxia Pharmaceuticals Announces Upcoming Presentations at the Osteoarthritis Research Society International World Congress 2024

Retrieved on: 
Thursday, April 11, 2024
OA, Fluticasone, Pain, Patient, Knee, Randomness, OARSI, Osteoarthritis Research Society International, Osteoarthritis, Abstract, TSX, Pharmacokinetics, MRI, Diabetes, World Congress, Pharmaceutical industry

VICTORIA, BC, April 11, 2024 /PRNewswire/ - Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (TSX: EPRX) (NASDAQ: EPRX), a clinical-stage biotechnology company leveraging its proprietary Diffusphere™ technology to optimize drug delivery for applications with significant unmet need, today announced that the Company will present two abstracts at the upcoming Osteoarthritis Research Society International ("OARSI") World Congress 2024.

Key Points: 
  • VICTORIA, BC, April 11, 2024 /PRNewswire/ - Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (TSX: EPRX) (NASDAQ: EPRX), a clinical-stage biotechnology company leveraging its proprietary Diffusphere™ technology to optimize drug delivery for applications with significant unmet need, today announced that the Company will present two abstracts at the upcoming Osteoarthritis Research Society International ("OARSI") World Congress 2024.
  • The meeting is being held in Vienna, Austria from April 18-21, 2024.
  • In combination with our pre-clinical and MRI results, these data suggest a potential best-in-class candidate in terms of managing cartilage health."
  • Poster Title: Pharmacokinetics of EP-104IAR Long-lasting Fluticasone Propionate for Intra Articular Injection in 163 Subjects from SPRINGBOARD, a Phase 2 Study in Knee Osteoarthritis.

Metagenomi to Present at Upcoming Scientific Meetings

Retrieved on: 
Monday, April 8, 2024
Congress, Patient, Gene, World Congress, World Federation of Hemophilia, MD, World government, Society, Cell, MGX, WFH, Annual general meeting, Pharmaceutical industry

EMERYVILLE, Calif., April 08, 2024 (GLOBE NEWSWIRE) -- Metagenomi, Inc. (Nasdaq: MGX), a precision genetic medicines company committed to developing curative therapeutics for patients using its proprietary, comprehensive metagenomics-derived gene editing toolbox, today announced that the Company will present at two upcoming scientific meetings: a late breaking oral presentation at The World Federation of Hemophilia (WFH) World Congress, taking place April 21 – 24, 2024 in Madrid, Spain and two poster presentations at the American Society of Gene & Cell Therapy (ASGCT) 2024 Annual Meeting, taking place May 7 – 11, 2024, in Baltimore, MD and virtually.

Key Points: 
  • -   Oral Presentation at World Federation of Hemophilia (WFH) World Congress, April 23, 2024
    -   Two Posters at American Society of Gene & Cell Therapy (ASGCT) 2024 Annual Meeting, May 8 & 9, 2024
    EMERYVILLE, Calif., April 08, 2024 (GLOBE NEWSWIRE) -- Metagenomi, Inc. (Nasdaq: MGX), a precision genetic medicines company committed to developing curative therapeutics for patients using its proprietary, comprehensive metagenomics-derived gene editing toolbox, today announced that the Company will present at two upcoming scientific meetings: a late breaking oral presentation at The World Federation of Hemophilia (WFH) World Congress, taking place April 21 – 24, 2024 in Madrid, Spain and two poster presentations at the American Society of Gene & Cell Therapy (ASGCT) 2024 Annual Meeting, taking place May 7 – 11, 2024, in Baltimore, MD and virtually.

Pacira BioSciences Announces PCRX-201 Granted Regenerative Medicine Advance Therapy (RMAT) Designation for the Treatment of Osteoarthritis of the Knee

Retrieved on: 
Wednesday, March 13, 2024
Knee, Congress, Biologics license application, Patient, ATMP, Research, World Congress, OARSI, European Medicines Agency, WOMAC, Osteoarthritis Research Society International, KOOS, Drug development, Safety, Pain, Vasopressin receptor 2, DVD-Audio, Food, Osteoarthritis, FDA, BLA, Pharmaceutical industry

TAMPA, Fla., March 13, 2024 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to non-opioid pain management and regenerative health solutions, today announced that the U.S. Food and Drug Administration (FDA) has granted Regenerative Medicine Advanced Therapy (RMAT) designation to PCRX-201 (enekinragene inzadenovec), the company’s novel, intra-articular helper-dependent adenovirus (HDAd) gene therapy product candidate that codes for interleukin-1 receptor antagonist (IL-1Ra), for the treatment of osteoarthritis of the knee.

Key Points: 
  • PCRX-201 was well tolerated, with efficacy observed through at least 52 weeks at all doses and cohorts.
  • Preliminary 36-week data were presented at the Osteoarthritis Research Society International (OARSI) 2023 World Congress, the premier annual international forum in osteoarthritis research and treatment.
  • The 52-week data have been accepted for presentation at OARSI 2024 taking place in Vienna, Austria in April 2024 and the company expects to present 104-week efficacy and safety data later this year.
  • PCRX-201 was also granted Advanced Therapy Medicinal Products (ATMP) designation by the European Medicines Agency in May 2023.

Deputy Minister of Ukraine, Nataliia Kalmykova, will be speaking at the LA Convention Center this week

Retrieved on: 
Tuesday, March 12, 2024
Karma, SBMT, Brain, Congress, Brain mapping, Neuroscience, Neurology, Multiple sclerosis, Alzheimer's disease, Ophthalmology, Doe, Knowledge, Los Angeles Convention Center, Associate, Journal, Loma Linda University, Disease, Military medicine, World Congress, AI, Cadaver, Neuro-oncology, Society, Michelson Medical Research Foundation, Journal of Alzheimer's Disease, NASA, Neuroelectrics, Regenerative medicine, Therapy, Spine, Multimedia, Springer Nature, B cell, Neurosurgery

Deputy Minister of Ukraine, Nataliia Kalmykova, will be amongst keynotes ; Ukrainian neurosurgeons from the frontline will also be speaking about combat casualty care and participate in the convention in person.

Key Points: 
  • Deputy Minister of Ukraine, Nataliia Kalmykova, will be amongst keynotes ; Ukrainian neurosurgeons from the frontline will also be speaking about combat casualty care and participate in the convention in person.
  • Since the beginning of the war in Ukraine, SBMT has been supporting Ukrainian doctors with training and medical equipment.
  • The SBMT World Congress is renowned for its comprehensive program, offering a diverse range of presentations, hands-on workshops, Bioskills cadaver labs, and an expansive exhibition hall.
  • Attendees can expect to engage with cutting-edge research, innovative technologies, and expert insights that are shaping the future of neurosciences and neurotechnology.

A Fond Farewell: Memories to Treasure from MWC 2024

Retrieved on: 
Monday, March 4, 2024
Mobile virtual network operator, Life, Congress, Attention, MWC, Atmosphere, World Congress, Nightclub

HONG KONG, March 4, 2024 /PRNewswire/ -- As IPLOOK reflects on its successful participation in MWC 2024, the company is left with countless memories, insights and opportunities that will continue to inspire its team long after the event has ended.

Key Points: 
  • HONG KONG, March 4, 2024 /PRNewswire/ -- As IPLOOK reflects on its successful participation in MWC 2024, the company is left with countless memories, insights and opportunities that will continue to inspire its team long after the event has ended.
  • IPLOOK's booth was a hub of activity throughout the 4-day event, drawing in crowds of attendees eager to learn more about IPLOOK's innovative core network solutions.
  • Some of the key achievements and gains for IPLOOK at MWC 2024 included:
    Strong partnerships forged: IPLOOK nailed several new partnerships with leading telecom companies, expanding its reach and impact in the industry.
  • This year's MWC, as per its theme "Future First", was a testament to the power of technology to transform our future life.

AI, Cyber Security, 5G and Tech - Verizon will bring it together at Mobile World Congress Barcelona

Retrieved on: 
Thursday, February 15, 2024
Robotics, EVP, Artificial intelligence, AI, Mobile, Gen, Research, Internet, GSMA, Connective tissue, Sport, Mobile World Congress, Virtual reality, Software as a service, World Congress, Congress, Verizon Business, Woman

Connectivity is what artificial intelligence, virtual reality, robotics, the Internet of Things, smart manufacturing and streaming entertainment all have in common.

Key Points: 
  • Connectivity is what artificial intelligence, virtual reality, robotics, the Internet of Things, smart manufacturing and streaming entertainment all have in common.
  • At Mobile World Congress Barcelona, Verizon’s leaders will share how the power of connectivity is the foundation of how we all live and work.
  • It’s no coincidence that the rise of 5G networks pulled decades of AI work out of research labs and into all of our lives.
  • The reach, breadth and capacity of 5G networks are the lifeblood of innovation and GSMA forecasts they will account for more than 90% of mobile subscriptions by 2030.

binx health Enters into National Distribution Agreement with Cardinal Health to Increase Access to the CLIA-waived, FDA-cleared binx io

Retrieved on: 
Monday, February 12, 2024
Cardinal, Hospital, POC, FDA, Infection, Female, Pharmacy, Cardinal Health, Emergency, World Congress, Patient, CLIA, Diagnosis, Male, Gonorrhea, Chlamydia, STI, Medical imaging

Collaborating with Cardinal Health provides binx health with additional access to the acute clinical care settings via its vast sales network in the market.

Key Points: 
  • Collaborating with Cardinal Health provides binx health with additional access to the acute clinical care settings via its vast sales network in the market.
  • We are proud that we have earned their trust in binx and the binx io," said Jeffrey Luber, binx health’s Chief Executive Officer.
  • With this distribution collaboration, together binx health and Cardinal Health teams will help improve access to the treatment of CT/NG.
  • For more information about the binx io, visit mybinxhealth.com/binx-io or contact your Cardinal Health representative.